🧪
hypothesis

Multi-Target Microglial Metabolic Reprogramming

Hypothesis

Multi-Target Microglial Metabolic Reprogramming

Combinatorial targeting of TREM2, APOE, and CLU network with metabolic reprogramming toward anti-inflammatory microglial phenotypes.
🧬 ['TREM2', 'APOE', 'CLU']🩺 neurodegeneration🎯 Composite 48%💱 $0.56▼8.2%active
EvidencePending (0%)📖 5 cit🗣 1 debates 5 support 1 oppose
✓ All Quality Gates Passed
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite48%

🧪 Overview

Combinatorial targeting of TREM2, APOE, and CLU network with metabolic reprogramming toward anti-inflammatory microglial phenotypes

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Microglial Dysfunction<br/>AD Neuroinflammation"]
    B["TREM2 Signaling Activation<br/>Lipid Phagocytosis Enhancement"]
    C["APOE Modulation<br/>Cholesterol Efflux Optimization"]
    D["CLU Clusterin Activity<br/>Amyloid Chaperone and Clearance"]
    E["Combinatorial Network Targeting<br/>TREM2 plus APOE plus CLU"]
    F["Metabolic Reprogramming<br/>Anti-Inflammatory Microglial Phenotype"]
    G["Amyloid and Lipid Burden Cleared<br/>Neuroinflammation Resolved"]
    H["Neuroprotective Microglial State<br/>AD Progression Slowed"]
    A --> B
    A --> C
    A --> D
    B --> E
    C --> E
    D --> E
    E --> F
    F --> G
    G --> H
    style E fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

⚖️ Evidence

⚖️ Evidence Matrix5 supports0 contradicts
Supports
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.
Immunity2017PMID:28930663medium
Supports
TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.
Cell2022PMID:36306735medium
Supports
TREM2, microglia, and Alzheimer's disease.
Mech Ageing Dev2021PMID:33516818medium
Supports
Microglia and TREM2.
Neuropharmacology2024PMID:38821351medium
Supports
A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.
Cell2017PMID:28602351medium
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — ['TREM2'

No curated PDB or AlphaFold mapping for ['TREM2' yet. Search RCSB →

💉 Clinical Trials (5)

0
Active
0
Completed
0
Total Enrolled
PHASE1
Highest Phase
The Analysis of Gene Variants Related to POCD in Elderly PatientsUnknown
UNKNOWN·NCT05419596 · Istanbul University
Cognitive Dysfunction
Urologic Surgery
Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's DiseaseUnknown
COMPLETED·NCT06224920 · Ludwig-Maximilians - University of Munich
Alzheimer Disease Corticobasal Syndrome
magnetic resonance imaging electroencephalography blood and CSF biomarker
DORA and LP in Alzheimer's Disease BiomarkersPHASE2
RECRUITING·NCT06274528 · Washington University School of Medicine
Alzheimer Disease
Lemborexant 10 mg Lemborexant 20mg Placebo
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease PatientsPHASE2
COMPLETED·NCT04388254 · Cassava Sciences, Inc.
Alzheimer Disease
Simufilam 100 mg oral tablet Placebo
Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy VolunteersPHASE1
COMPLETED·NCT04570644 · AZTherapies, Inc.
Healthy Volunteers Alzheimer Disease
ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for ['TREM2', 'APOE', 'CLU'] →

No DepMap CRISPR Chronos data found for ['TREM2', 'APOE', 'CLU'].

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0580
Events (7d)
1
Price History
▼8.2%

💾 Resource Usage

LLM Tokens
14,692
$0.0882
Total Cost
$0.0882

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF RNA-seq and metabolomics are performed on sorted CD11b+CD45+ microglia from post-mortem prefrontal cortex of AD cases with TREM2-R47H variants (n=30), APOE4/4 homozygotes (n=30), and CLU-rs11136000Microglial transcriptomic and metabolomic signatures in carriers of TREM2, APOE4, and CLU risk variants will show a pro-glycolytic, anti-oxidative metabolic pro— no observation —pending0.60
IF 5xFAD mice receive combined TREM2 agonism (biweekly anti-TREM2 antibody, 2 mg/kg), APOE4-neutralization (CRISPRi-lentivirus in hippocampus), and CLU silencing (ASO, 50 μg/kg/week) plus NAD+ repletiTriple-target + metabolic reprogramming will reduce amyloid plaque area by ≥40% (stereology), increase microglia branching complexity (Iba1 Sholl analysis), and— no observation —pending0.55
🔮 Falsifiable Predictions (2)
pendingconf 60%
IF RNA-seq and metabolomics are performed on sorted CD11b+CD45+ microglia from post-mortem prefrontal cortex of AD cases with TREM2-R47H variants (n=30), APOE4/4 homozygotes (n=30), and CLU-rs11136000 risk carriers (n=30) matched for age/PMI/Braak stage, THEN risk allele carriers will show elevated
Predicted outcome: Microglial transcriptomic and metabolomic signatures in carriers of TREM2, APOE4, and CLU risk variants will show a pro-glycolytic, anti-oxidative met
Falsification: No significant difference in glycolytic vs. oxidative phosphorylation metabolites between risk carriers and non-carriers (p>0.05, ANOVA with Bonferroni correction) OR HIF1α target genes show equal or
pendingconf 55%
IF 5xFAD mice receive combined TREM2 agonism (biweekly anti-TREM2 antibody, 2 mg/kg), APOE4-neutralization (CRISPRi-lentivirus in hippocampus), and CLU silencing (ASO, 50 μg/kg/week) plus NAD+ repletion (nicotinamide riboside 400 mg/kg diet) from 3-4 months of age for 12 weeks, THEN amyloid plaque b
Predicted outcome: Triple-target + metabolic reprogramming will reduce amyloid plaque area by ≥40% (stereology), increase microglia branching complexity (Iba1 Sholl anal
Falsification: Plaque burden does not decrease by ≥40% OR microglia remain dystrophic (ramified endpoints <10 Sholl intersections) OR spatial memory shows no improvement (escape latency >35 seconds) despite confirme
View on SciDEX ↗